Search

Octisalate

Octyl salicylate is used to augment the UVB protection in a sunscreen. Salicylates are weak UVB absorbers and they are generally used in combination with other UV filters. … Octyl salicylate appears to have a good safety profile. It covers wavelength in the range 295-315 nm, peak at 307-310 nm. It is an ester of salicylic acid and 2-ethylhexanol.

Hexaminolevulinate

In Europe, Hexaminolevulinate is marketed under the brand Hexvix®. … of a prior cystoscopy.

Telaprevir

Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label]. … Approved in May 2011 by the FDA, Incivek was indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].

Ferrous gluconate

Riociguat

Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

Tezepelumab

[A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]

Riltozinameran

BA.4, BA.5) which, although similar, may behave differently from one another.[L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1. … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.

Dasabuvir

Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label]. … Dasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA [FDA Label].

Dihydrocodeine

It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

Daclatasvir

Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. … The SVR12 in HCV genotype 1a-infected treatment-naïve subjects without and with cirrhosis undergoing daclatasvir and [DB08934] therapy were 88% and 99%, respectively [FDA Label].